PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
PMV Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 20,945 | $26,181.25 | $29,218.27 | $3,037.02 | 11.6% |
| AWM Accurate Wealth Management LLC Accurate Wealth Management LLC | 50,000 | $62,000 | $71,000 | $9,000 | 14.52% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $3.72 | $3.93 | $0.21 | 5.65% |
| RJ Rebecca Judd Pathstone Holdings, LLC | 17,487 | $18,536 | $22,383.36 | $3,847.36 | 20.76% |
| BCG BIT Capital GmbH BIT Capital GmbH | 123,555 | $153,208 | $172,977 | $19,769 | 12.9% |
PMV Pharmaceuticals, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JJ Jeff Jones Oppenheimer | 4,035.79 | $5,044.74 | $5,650.11 | $605.37 | 12% |
PMV Pharmaceuticals, Inc. (PMVP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has PMV Pharmaceuticals, Inc. ever had a stock split?
PMV Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David H. Mack CEO | NASDAQ (NGS) Exchange | 69353Y103 CUSIP |
| US Country | 54 Employees | - Last Dividend | - Last Split | 25 Sep 2020 IPO Date |
Overview
PMV Pharmaceuticals, Inc. is a precision oncology company engaged in the groundbreaking field of developing therapeutic solutions targeted at specific mutations responsible for cancer. The focal point of their research and development efforts lies in tackling mutations of the p53 gene, which plays a crucial role in preventing cancer formation, thereby acting as a tumor suppressor. Founded initially as PJ Pharmaceuticals, Inc., the company underwent a rebranding to PMV Pharmaceuticals, Inc. in July 2013, marking the beginning of a dedicated pursuit towards leveraging precision medicine to battle the most challenging cancers. Headquartered in Princeton, New Jersey, and established in 2013, PMV Pharmaceuticals has quickly positioned itself as a prominent player in the quest for innovative cancer treatments.
Products and Services
- PC14586
